Evidence map›Paper›PMID 42503230›Full record

Observational studyThe Prostate2026

Evaluation of [

Roopal Agrawal, Rahul V Parghane, Amit Joshi, Kumar Prabhash, Sandip Basu

Abstract readObservational StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The Prostate, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Roopal AgrawalRadiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Mumbai, Parel, India.
Rahul V ParghaneRadiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Mumbai, Parel, India.
Amit JoshiHomi Bhabha National Institute, Mumbai, India.
Kumar PrabhashHomi Bhabha National Institute, Mumbai, India.
Sandip BasuRadiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Centre Annexe, Mumbai, Parel, India.ORCID 0000-0001-6607-2558

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA subset of prostate cancer progresses to aggressive state of metastatic castration-resistant prostate cancer (mCRPC), wherein multiple therapeutic options demonstrate limited success rates. In this observational study, we aimed to evaluate the efficacy, toxicity, and survival outcomes of (a) [

methodsThe study reviewed the medical records of mCRPC patients who had documented disease progression following treatment with androgen receptor pathway inhibitors and docetaxel. These patients had multiple therapeutic options and treated with [

resultsA total 66 mCRPC patients were included and analyzed in this study. These patients were divided into two cohorts. Cohort 1 (n = 49 patients) received initial course of [

conclusionPostdocetaxel mCRPC patients with progressive disease following initial course of [

Indexed as

ActiniumDipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantTaxoidsAdministration, MetronomicAdministration, OralAgedHumansMaleProstate-Specific AntigenRadioisotopesRadiopharmaceuticalsRetrospective StudiesTreatment Outcome(225)Ac-PSMA-617ActiniumcabazitaxelDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177lutetium (177Lu) vipivotide tetraxetanProstate-Specific AntigenRadioisotopesRadiopharmaceuticalsTaxoids[177Lu]Lu‐PSMA‐617[225Ac]Ac‐PSMA‐617cabazitaxelchemotherapymetastatic castrate resistant prostate carcinomametronomic cyclophosphosphamidepeptide receptor radioligand therapyPERCISTprogression free survival and overall survivalrechallenge [177Lu]Lu‐PSMA‐617 RLTRECIPRECISTtargeted alpha therapy

Identifiers

PMID42503230
PMCPMC13526414

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.